Results: The cohort of (n = 204) were mostly female (58%) and white (62%), with 48% (n = 98) with HAE Type I, II, or ACE-inhibitor-induced angioedema
Its Real Alternatives The intellectually honest conclusion: GHK-Cu belongs in a routine as a well-tolerated adjunct with a plausible mechanism, not as a proven primary anti-aging intervention
October 17, 2024: Discovery Battles Continue in Ozempic Lawsuit Attorneys continue to argue over what discovery should be allowed in the multidistrict litigation pending out of the Eastern District of Pennsylvania
The only downside is that dozens of companies are peddling "miracle" supplements, and they can drown out the safer, more effective options on the market
and sometimes they turn out
The Phase 2 trial indicated that retatrutide is similar in terms of safety and side effects to tirzepatide and semaglutide, and the TRIUMPH-1 Phase 3 trial confirmed a manageable safety profile at all doses tested